Regulation of lipid metabolism by soy protein and its implication in diseases mediated by lipid disorders

Journal of Nutritional Biochemistry

Volumn 17, Issue 6, 2006, Pages 365-373

  Torres, Nimbe ^a   Torre Villalvazo, Ivan ^a   Tovar, Armando R ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Diabetes; Kidney; Lipogenesis; Lipotoxicity; Obesity; SREBP 1

Indexed keywords

BOWMAN BIRK INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCAGON; GLYCININ; HOMOCYSTEINE; IMMUNOGLOBULIN 7S; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PROTEIN LUNASIN; PROTEIN OSMOTIN; SOYBEAN PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BILE ACID; CHOLESTEROL; SREBF1 PROTEIN, HUMAN;

ADIPOCYTE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG MECHANISM; ENZYME RELEASE; FATTY ACID TRANSPORT; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; METABOLIC DISORDER; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTAKE; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BIOSYNTHESIS; BLOOD; DRUG EFFECT; ENZYMOLOGY; HOMEOSTASIS; HYPERLIPIDEMIA; INTESTINE ABSORPTION; KIDNEY DISEASE; LIVER; LIVER DISEASE; METABOLISM; PHYSIOLOGY;

ANIMALIA; GLYCINE MAX;

ADIPOCYTES; BILE ACIDS AND SALTS; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS; GLUCAGON; HOMEOSTASIS; HOMOCYSTEINE; HUMANS; HYPERLIPIDEMIAS; INSULIN; INTESTINAL ABSORPTION; KIDNEY DISEASES; LIPID METABOLISM; LIVER; LIVER DISEASES; OBESITY; SOYBEAN PROTEINS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 33746102594     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2005.11.005     Document Type: Review

References (98)

1. Young V.R. Soy protein in relation to human protein and amino acid nutrition. J Am Diet Assoc 91 (1991) 828-835
2. Tovar A.R., Ascencio C., and Torres N. Soy protein, casein, and zein regulate histidase gene expression by modulating serum glucagon. Am J Physiol Endocrinol Metab 283 (2002) E1016-E1022
3. Tovar A.R., Murguía F., Cruz C., Hernández-Pando R., Aguilar-Salinas C.A., Pedraza-Chavarri J., et al. A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephritic syndrome. J Nutr 132 (2002) 2562-2569
4. Nagata C., Shimizu H., Takami R., Hayashi M., Takeda M., and Yasuda K. Soy product intake is inversely associated with serum homocysteine level in premenopausal Japanese women. J Nutr 133 (2003) 797-800
5. Sitori C.R., Lovati M.R., Manzoni C., Monetti M., Pazzucconi F., and Gatti E. Soy and cholesterol reduction: clinical experience. J Nutr 125 (1995) 598S-605S
6. Baum J.A., Teng H., Erdman J.W., Weigel R.M., Klein B.P., Persky V.W., et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr 68 (1998) 545-551
7. Tovar-Palacio C., Potter S.M., Hafermann J.C., and Shay N.F. Intake of soy protein and soy protein extracts influences lipid metabolism and hepatic gene expression in gerbils. J Nutr 128 (1998) 839-842
8. Rosell M.S., Appleby P.N., Spencer E.A., and Key T.J. Soy intake and blood cholesterol concentrations: a cross-sectional study of 1033 pre- and postmenopausal women in the Oxford arm of the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 80 (2004) 1391-1396
9. Sanchez A., and Hubbard R.W. Plasma amino acids and the insulin/glucagon ratio as an explanation for the dietary protein modulation of atherosclerosis. Med Hypotheses 36 (1991) 27-32
10. Kelemen L.E., Kushi L.H., Jacobs D.R., and Cerhan J.R. Associations of dietary protein with disease and mortality in a prospective study of postmenopausal women. Am J Epidemiol 161 (2005) 239-249
11. Radcliffe J.D., and Czajka-Narins D.M. Partial replacement of dietary casein with soy protein isolate can reduce the severity of retinoid-induced hypertriglyceridemia. Plant Foods Hum Nutr 52 (1998) 97-108
12. Anderson J.W., and Hoie L.H. Weight loss and lipid changes with low-energy diets: comparator study of milk-based versus soy-based liquid meal replacement interventions. J Am Coll Nutr 24 (2005) 210-216
13. Anderson J.W., Johnstone B.M., and Cook-Newell M.E. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333 (1995) 276-278
14. Zhan S., and Ho S.C. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 81 (2005) 397-408
15. Jenkins D.J., Kendall C.W., Marchie A., Faulkner D.A., Wong J.M., de Souza R., et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290 (2003) 502-510
16. Merritt J.C. Metabolic syndrome: soybean foods and serum lipids. J Natl Med Assoc 96 (2004) 1032-1041
17. Sanchez A., Rubano D.A., Shavlik G.W., Hubbard R.W., and Horning M.C. Cholesterolemic effects of the lysine/arginine ratio in rabbits after initial early growth. Arch Latinoam Nutr 38 (1988) 229-238
18. Carroll K.K. Hypercholesterolemia and atherosclerosis: effect of dietary protein. Fed Proc 41 (1982) 2792-2796
19. Kotsopoulos D., Dalais F.S., Liang Y.L., McGrath B.P., and Teede H.J. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric 3 (2000) 161-167
20. Anderson J.J. Soy phytoestrogens, lipid reductions, and atherosclerosis delay in ovariectomized primates. J Clin Endocrinol Metab 86 (2001) 39-40
21. Sewell A., Hollenbeck C.B., and Bruce B. The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab 87 (2002) 118-121
22. Calbet J.A., and MacLean D.A. Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans. J Nutr 132 (2002) 2174-2182
23. Radcliffe J.D., and Czajka-Narins D.M. Use of arginine to reduce the severity of retinoid-induced hypertriglyceridemia. Nutr Cancer 36 (2000) 200-206
24. Madani S., Prost J., and Belleville J. Dietary protein level and origin (casein and highly purified soybean protein) affect hepatic storage, plasma lipid transport, and antioxidative defense status in the rat. Nutrition 16 (2000) 368-375
25. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
26. Sakai J., Duncan E.A., Rawson R.B., Hua X., Brown M.S., and Goldstein J.L. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 85 (1996) 1037-1046
27. Sakai J., Nohturfft A., Goldstein J.L., and Brown M.S. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem 273 (1998) 5785-5793
28. Matsuda M., Korn B.S., Hammer R.E., Moon Y.A., Komuro R., Horton J.D., et al. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev 15 (2001) 1206-1216
29. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002) 1125-1131
30. Stoeckman A.K., and Towle H.C. The role of SREBP-1c in nutritional regulation of lipogenic enzyme gene expression. J Biol Chem 277 (2002) 27029-27035
31. Amemiya-Kudo M., Shimano H., Hasty A.H., Yahagi N., Yoshikawa T., Matsuzaka T., et al. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 43 (2002) 1220-1235
32. Foretz M., Pacot C., Dugail I., Lemarchand P., Guichard C., Le Liepvre X., et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 19 (1999) 3760-3768
33. Zhang Y., Yin L., and Hillgartner F.B. SREBP-1 integrates the actions of thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCalpha transcription in hepatocytes. J Lipid Res 44 (2003) 356-368
34. Azzout-Marniche D., Becard D., Guichard C., Foretz M., Ferre P., and Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J 350 (2000) 389-393
35. Ascencio C., Torres N., Isoard-Acosta F., Gómez-Pérez F.J., Hernández-Pando R., and Tovar A.R. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 134 (2004) 522-529
36. Mullen E., Brown R.M., Osborne T.F., and Shay N.F. Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBP-regulated genes in HepG2 cells. J Nutr 134 (2004) 2942-2947
37. Dobrzyn A., and Ntambi J.M. The role of stearoyl-CoA desaturase in the control of metabolism. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 35-41
38. Ntambi J.M., Miyazaki M., Stoehr J.P., Lan H., Kendziorski C.M., Yandell B.S., et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A 99 (2002) 11482-11486
39. Liew C.F., Groves C.J., Wiltshire S., Zeggini E., Frayling T.M., Owen K.R., et al. Analysis of the contribution to Type 2 diabetes susceptibility of sequence variation in the gene encoding stearoyl-CoA desaturase, a key regulator of lipid and carbohydrate metabolism. Diabetologia 47 (2004) 2168-2175
40. Tovar A.R., Torre-Villalvazo I., Ochoa M., Elias A.L., Ortiz V., Aguilar-Salinas C.A., et al. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 46 (2005) 1823-1832
41. Huff M.W., and Carroll K.K. Effects of dietary protein on turnover, oxidation, and absorption of cholesterol, and on steroid excretion in rabbits. J Lipid Res 21 (1980) 546-558
42. Potter S.M. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr 125 (1995) 606S-611S
43. Tovar A., Manzano N., and Torres N. Regulación del metabolismo del colesterol y ácidos grasos en el síndrome nefrótico experimental por las Proteínas que se Unen a los Elementos Regulatorios de Esteroles (SREBP's): efecto de la soya. Gaceta Med Mex 141 (2005) 27-35
44. Shimomura I., Bashmakov Y., and Horton J.D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274 (1999) 30028-30032
45. Kolehmainen M., Vidal H., Alhava E., and Uusitupa M.I. Sterol regulatory element binding protein 1c (SREBP-1c) expression in human obesity. Obes Res 9 (2001) 706-712
46. Hegarty B.D., Bobard A., Hainault I., Ferre P., Bossard P., and Foufelle F. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. Proc Natl Acad Sci U S A 102 (2005) 791-796
47. Briaud I., Harmon J.S., Kelpe C.L., Segu V.B., and Poitout V. Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 50 (2001) 315-321
48. Unger R.H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 14 (2003) 398-403
49. Sharma S., Adrogue J.V., Golfman L., Uray I., Lemm J., Youker K., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18 (2004) 1692-1700
50. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
51. Tamura S., and Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 115 (2005) 1139-1142
52. Guidorizzi de Siqueira A.C., Cotrim H.P., Rocha R., Carvalho F.M., de Freitas L.A., Barreto D., et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 17 (2005) 837-841
53. Unger R.H., and Zhou Y.T. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50 (2001) S118-S121
54. Unger R.H. Lipotoxic diseases. Annu Rev Med 53 (2002) 319-336
55. Abrams G.A., Kunde S.S., Lazenby A.J., and Clements R.H. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 40 (2004) 475-483
56. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
57. Mehendale H.M. PPAR-alpha: a key to the mechanism of hepatoprotection by clofibrate. Toxicol Sci 57 (2000) 187-190
58. Ip E., Farrell G.C., Robertson G., Hall P., Kirsch R., and Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38 (2003) 123-132
59. Lelliott C., and Vidal-Puig A.J. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord 28 (2004) S22-S28
60. Berge R.K., Tronstad K.J., Berge K., Rost T.H., Wergedahl H., Gudbrandsen O.A., et al. The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie 87 (2005) 15-20
61. Ishihara K., Oyaizu S., Fukuchi Y., Mizunoya W., Segawa K., Takahashi M., et al. A soybean peptide isolate diet promotes postprandial carbohydrate oxidation and energy expenditure in Type II diabetic mice. J Nutr 133 (2003) 752-757
62. Fortuno A., Rodriguez A., Gomez-Ambrosi J., Fruhbeck G., and Diez J. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 59 (2003) 51-60
63. Shimabukuro M., Koyama K., Chen G., Wang M.Y., Trieu F., Lee Y., et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl 94 (1997) 4637-4641
64. Inoue M., Maehata E., Yano M., Taniyama M., and Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with Type 2 diabetes. Metabolism 54 (2005) 281-286
65. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21 (2000) 697-738
66. Ding X., Saxena N.K., Lin S., Xu A., Srinivasan S., and Anania F.A. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 166 (2005) 1655-1669
67. Nadler S.T., Stoehr J.P., Schueler K.L., Tanimoto G., Yandell B.S., and Attie A.D. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 97 (2000) 11371-11376
68. Nadler S.T., and Attie A.D. Please pass the chips: genomic insights into obesity and diabetes. J Nutr 131 (2001) 2078-2081
69. Horton J.D., Shimomura I., Ikemoto S., Bashmakov Y., and Hammer R.E. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J Biol Chem 278 (2003) 36652-36660
70. Nagasawa A., Fukui K., Kojima M., Kishida K., Maeda N., Nagaretani H., et al. Divergent effects of soy protein diet on the expression of adipocytokines. Biochem Biophys Res Commun 311 (2003) 909-914
71. Farmer S.R. Regulation of PPARgamma activity during adipogenesis. Int J Obes Relat Metab Disord 29 (2005) S13-S16
72. Brun R.P., and Spiegelman B.M. PPAR gamma and the molecular control of adipogenesis. J Endocrinol 155 (1997) 217-218
73. Mezei O., Banz W.J., Steger R.W., Peluso M.R., Winters T.A., and Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 133 (2003) 1238-1243
74. Gustafson B., Jack M.M., Cushman S.W., and Smith U. Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 308 (2003) 933-939
75. Gianazza E., Eberini I., Arnoldi A., Wait R., and Sirtori C.R. A proteomic investigation of isolated soy proteins with variable effects in experimental and clinical studies. J Nutr 133 (2003) 9-14
76. Manzoni C., Lovati M.R., Gianazza E., Morita Y., and Sirtori C.R. Soybean protein products as regulators of liver low-density lipoprotein receptors: I. α-α′ rich commercial soy concentrate and α′ deficient mutant differently affect low-density lipoprotein receptor activation. J Agric Food Chem 46 (1998) 2481-2484
77. Lovati M.R., Manzoni C., Gianazza E., Arnoldi A., Kurowska E., Carroll K.K., et al. Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. J Nutr 130 (2000) 2543-2549
78. Manzoni C., Duranti M., Eberini I., Scharnag H., Marz W., Castiglioni S., et al. Subcellular localization of soybean 7S globulin in HepG2 cells and LDL receptor up-regulation by its alpha′ constituent subunit. J Nutr 133 (2003) 2149-2155
79. Matoba N., Doyama N., Yamada Y., Maruyama N., Utsumi S., and Yoshikawa M. Design and production of genetically modified soybean protein with anti-hypertensive activity by incorporating potent analogue of ovokinin (2-7). FEBS Lett 497 (2001) 50-54
80. Bringe N.A. U.S. Patent 6,171,640. B1: High a-conglycinin products and their use (2001), Monsanto Company, St. Louis (Mo)
81. Nagaoka S., Awano T., Nagata N., Masaoka M., Hori G., and Hashimoto K. Serum cholesterol reduction and cholesterol absorption inhibition in CaCo-2 cells by a soyprotein peptic hydrolyzate. Biosci Biotechnol Biochem 61 (1997) 354-356
82. Adams M.R., Golden D.L., Franke A.A., Potter S.M., Smith H.S., and Anthony M.S. Dietary soy beta-conglycinin (7S globulin) inhibits atherosclerosis in mice. J Nutr 134 (2004) 511-516
83. Pupovac J., and Anderson G.H. Dietary peptides induce satiety via cholecystokinin-A and peripheral opioid receptors in rats. J Nutr 132 (2002) 2775-2780
84. Nishi T., Hara H., and Tomita F. Soybean beta-conglycinin peptone suppresses food intake and gastric emptying by increasing plasma cholecystokinin levels in rats. J Nutr 133 (2003) 352-357
85. Nishi T., Hara H., Asano K., and Tomita F. The soybean beta-conglycinin beta 51-63 fragment suppresses appetite by stimulating cholecystokinin release in rats. J Nutr 133 (2003) 2537-2542
86. Friedman M., and Brandon D.L. Nutritional and health benefits of soy proteins. J Agric Food Chem 49 (2001) 1069-1086
87. Choi S.K., Adachi M., and Utsumi S. Identification of the bile acid-binding region in the soy glycinin A1aB1b subunit. Biosci Biotechnol Biochem 66 (2002) 2395-2401
88. Kennedy A.R. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 68 (1998) 1406S-1412S
89. Jeong H.J., Park J.H., Yi Lam Y., and De Lumen B.O. Characterization of lunasin isolated from soybean. J Agric Food Chem 51 (2003) 7901-7906
90. Narasimhan M.L., Coca M.A., Jin J., Yamauchi T., Ito Y., Kadowaki T., et al. Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell Biol 17 (2005) 171-180
91. Foti P., Erba D., Riso P., Spadafranca A., Criscuoli F., and Testolin G. Comparison between daidzein and genistein antioxidant activity in primary and cancer lymphocytes. Arch Biochem Biophys 433 (2005) 421-427
92. Boersma B.J., Patel R.P., Kirk M., Jackson P.L., Muccio D., Darley-Usmar V.M., et al. Chlorination and nitration of soy isoflavones. Arch Biochem Biophys 368 (1999) 265-275
93. Pedraza-Chaverri J., Barrera D., Hernandez-Pando R., Medina-Campos O.N., Cruz C., Murguia F., et al. Soy protein diet ameliorates renal nitrotyrosine formation and chronic nephropathy induced by puromycin aminonucleoside. Life Sci 74 (2004) 987-999
94. Trujillo J., Ramirez V., Perez J., Torre-Villalvazo I., Torres N., Tovar A.R., et al. Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation. Am J Physiol Renal Physiol 288 (2005) F108-F116
95. Bilo H.J., Schaap G.H., Blaak E., Gans R.O., and Donker A.J. Effects of chronic and acute protein administration on renal function in patients with chronic renal insufficiency. Nephron 53 (1989) 181-187
96. Azadbakht L., Shakerhosseini R., Atabak S., Jamshidian M., Mehrabi Y., and Esmaill-Zadeh A. Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in Type II diabetes with nephropathy. Eur J Clin Nutr 57 (2003) 1292-1295
97. Teixeira S.R., Tappenden K.A., Carson L., Jones R., Prabhudesai M., Marshall W.P., et al. Isolated soy protein consumption reduces urinary albumin excretion and improves the serum lipid profile in men with Type 2 diabetes mellitus and nephropathy. J Nutr 134 (2004) 1874-1880
98. Stephenson T.J., Setchell K.D., Kendall C.W., Jenkins D.J., Anderson J.W., and Fanti P. Effect of soy protein-rich diet on renal function in young adults with insulin-dependent diabetes mellitus. Clin Nephrol 64 (2005) 1-11